Asset profile
BPL-003 (mebufotenin benzoate)
Small molecule
Evidence outlook · lead readout
NCT05870540 · Treatment Resistant Depression
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05870540: The core study randomized 196 participants and used a masked design with an active-placebo comparator; its primary endpoint was the clinical depression measure MADRS. Because the primary comparison has no posted results, it is not possible to determine whether the endpoint was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.